An Open-Label Evaluation of the Safety and Tolerability of SAGE-718 in Participants With Parkinson's Disease Mild Cognitive Impairment
Latest Information Update: 08 Jun 2023
At a glance
- Drugs Dalzanemdor (Primary)
- Indications Mild cognitive impairment; Parkinson's disease
- Focus Adverse reactions
- Acronyms PARADIGM
- Sponsors Sage Therapeutics
- 16 Feb 2023 According to a Sage Therapeutics media release, additional results from part B of this trial presented at European College of Neuropsychopharmacology(ECNP).
- 18 Oct 2022 Results assessing safety, tolerability, and efficacy of SAGE-718 in individuals with Parkinson's Disease Mild Cognitive Impairment, presented at the 35th Annual Congress of the European College of Neuropsychopharmacology.
- 26 Apr 2022 Results of part A presented at the 74th Annual Meeting of the American Academy of Neurology 2022